FIG. 6.

DXA scan evaluation of bones in PMPA-treated animals. DXA scans of the femur neck, global proximal femur, distal radius and ulna, and lumbar vertebrae (L2 to L4) were performed. Because each location gave similar results, the bone mineral density of lumbar vertebrae is given as a representative sample. Data for untreated animals are 13 measurements performed for 11 animals (including the two untreated animals whose data are presented in Table 6). Three macaques, animals 31042 (SIV infected), 31121 (uninfected), and 31122 (uninfected), received daily subcutaneous treatment with PMPA (10 mg/kg) from the first few weeks of life (Table 4). For comparison, animals 29276, 29045, and 29046 were started on prolonged high-dose PMPA treatment (30 mg/kg per day subcutaneously) within the first few weeks of life, with dosage reductions starting at 15 to 25 months of age (Table 2). The histories of the 10 animals which received short-term PMPA treatment (animals 30576, 30577, 30581, 30842, 30845, 30339, 30338, 30478, 30007, and 30162) are summarized in Table 1.